Welcome to the 5th Dermatology Drug Development Summit for Inflammatory Skin Diseases
Enhancing Next Generation Therapies Targeting Chronic Inflammatory and Auto-immune Skin Diseases
Innovating & Accelerating the Research, Development & Commercialization of Dermatological Treatments for Under-Served Inflammatory, and Auto-immune Skin Conditions, such as Atopic Dermatitis, Psoriasis, Vitiligo, Alopecia Areata.
In the unprecedented array, and steady stream of novel, topical, and systemic agents entering various phases of drug development, for critical inflammatory and autoimmune dermatological conditions this year, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, returns to Boston for 2021. As the world’s leading, and only forum committed to overcoming significant R&D hurdles, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions, this forum is not to be missed.
With the rising demand for consolidation and precision medicine, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year, the 5th annual meeting addresses advances and challenges in genetic discoveries, antibody drug development, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.
Ensure you join this year’s 150+ expert community, in-person, to uncover recent studies evaluating critical inflammatory and auto-immune pathways, gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo.
Leave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline, evaluate optimal dose and dosing regimen to support formulation changes for your approach, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market.
Join us in Boston this November
Find out more about how we'll be keeping you safe on site this November by visiting our 'Book With Confidence' page
Your 2021 Expert Speaker Faculty Includes:
Director, Division of Dermatology & Dental Products
US Head of Dermatology, Dupilumab
Research Fellow & Head of Topical & Advanced Drug Delivery, Pharmaceutical Sciences Small Molecules
Vice President Immunodermatology
Janssen (Johnson & Johnson)
Health & Safety Protocol
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.
Don’t just take our word for it…
Hear what 4th annual attendees have to say:
Proud to Partner with: